Assessing the clinical efficacy of quinidine in Brugada syndrome: "Mission: Impossible"?

Affiliations

¹ Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: bblhass@tasmc.health.gov.il.

Editorial

Bernard Belhassen. Heart Rhythm. 2017 Aug.

. 2017 Aug;14(8):1155-1156.

doi: 10.1016/j.hrthm.2017.04.034. Epub 2017 Apr 26.

¹ Department of Cardiology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. Electronic address: bblhass@tasmc.health.gov.il.

No abstract available

Comment on

The QUIDAM study: Hydroquinidine therapy for the management of Brugada syndrome patients at high arrhythmic risk.
Andorin A, Gourraud JB, Mansourati J, Fouchard S, le Marec H, Maury P, Mabo P, Hermida JS, Deharo JC, Delasalle B, Esnault S, Sadoul N, Davy JM, Leenhardt A, Klug D, Defaye P, Babuty D, Sacher F, Probst V. Andorin A, et al. Heart Rhythm. 2017 Aug;14(8):1147-1154. doi: 10.1016/j.hrthm.2017.04.019. Epub 2017 Apr 12. Heart Rhythm. 2017. PMID: 28411139 Clinical Trial.